CN108137607B - 适用于治疗与ntrk相关的病症的化合物和组合物 - Google Patents
适用于治疗与ntrk相关的病症的化合物和组合物 Download PDFInfo
- Publication number
- CN108137607B CN108137607B CN201680060799.0A CN201680060799A CN108137607B CN 108137607 B CN108137607 B CN 108137607B CN 201680060799 A CN201680060799 A CN 201680060799A CN 108137607 B CN108137607 B CN 108137607B
- Authority
- CN
- China
- Prior art keywords
- mixture
- tert
- stirred
- etoac
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210264P | 2015-08-26 | 2015-08-26 | |
| US62/210,264 | 2015-08-26 | ||
| PCT/US2016/048698 WO2017035354A1 (en) | 2015-08-26 | 2016-08-25 | Compounds and compositions useful for treating disorders related to ntrk |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108137607A CN108137607A (zh) | 2018-06-08 |
| CN108137607B true CN108137607B (zh) | 2021-04-06 |
Family
ID=56896780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680060799.0A Expired - Fee Related CN108137607B (zh) | 2015-08-26 | 2016-08-25 | 适用于治疗与ntrk相关的病症的化合物和组合物 |
Country Status (17)
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| KR102619444B1 (ko) | 2017-08-23 | 2023-12-29 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도 |
| EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| CN111936138B (zh) * | 2018-02-05 | 2024-03-08 | 深圳市原力生命科学有限公司 | 作为ep4受体拮抗剂的杂二环化合物 |
| JP2021519297A (ja) * | 2018-03-28 | 2021-08-10 | フォチョン・ファーマシューティカルズ・リミテッドFochon Pharmaceuticals, Ltd. | Trkキナーゼ阻害剤としての大環状化合物 |
| SG11202009681YA (en) | 2018-04-03 | 2020-10-29 | Blueprint Medicines Corp | Ret inhibitor for use in treating cancer having a ret alteration |
| ES3013815T3 (en) * | 2019-02-27 | 2025-04-15 | Ferro Therapeutics Inc | Compounds with ferroptosis inducing activity and methods of their use |
| HUE064283T2 (hu) | 2019-04-12 | 2024-02-28 | Blueprint Medicines Corp | Az (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il) piperazinil)-pirimidin-5-il)etán-1-amin kristályos formái és elõállítási eljárásai |
| KR20260083444A (ko) * | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| WO2021243192A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| CR20220666A (es) | 2020-05-29 | 2023-05-05 | Blueprint Medicines Corp | Composiciones farmacéuticas de pralsetinib |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| JP7833486B2 (ja) | 2021-05-26 | 2026-03-19 | アルカーメス,インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| CN113408945B (zh) * | 2021-07-15 | 2023-03-24 | 广西中烟工业有限责任公司 | 一种烤烟纯度的检测方法、装置、电子设备及存储介质 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2266519C (en) * | 1996-10-02 | 2007-01-23 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| RU2380369C9 (ru) | 2002-09-04 | 2011-07-10 | Шеринг Корпорейшн | Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| MXPA06011423A (es) * | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
| WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| CN102264736B (zh) | 2008-10-22 | 2013-08-14 | 阵列生物制药公司 | 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| AU2010352577A1 (en) * | 2010-05-05 | 2012-01-19 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as PKC-theta inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
| NZ703495A (en) | 2012-07-11 | 2018-02-23 | Blueprint Medicines Corp | Inhibitors of the fibroblast growth factor receptor |
| US20150218652A1 (en) * | 2012-08-31 | 2015-08-06 | The Regents Of The Unversity Of Colorado, A Body Corporate | Methods for diagnosis and treatment of cancer |
| JP6457942B2 (ja) | 2012-10-05 | 2019-01-23 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Gdf−8阻害剤 |
| EP2914621B1 (en) | 2012-11-05 | 2023-06-07 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| US9556181B2 (en) * | 2013-02-01 | 2017-01-31 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
| CN103965199B (zh) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| KR102148681B1 (ko) | 2013-02-21 | 2020-08-27 | 칼리토르 사이언시즈, 엘엘씨 | Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 |
| RU2015143517A (ru) | 2013-03-13 | 2017-04-19 | Дженентек, Инк. | Пиразолсодержащие соединения и их применения |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| JP6767875B2 (ja) | 2014-04-08 | 2020-10-14 | ライジェル ファーマシューティカルズ, インコーポレイテッド | Tgf−ベータ阻害剤としての2,3−二置換ピリジン化合物および使用方法 |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| HUE067779T2 (hu) | 2014-12-15 | 2024-11-28 | Cmg Pharmaceutical Co Ltd | Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| EP3259264B1 (en) | 2015-02-20 | 2022-07-27 | Rigel Pharmaceuticals, Inc. | Gdf-8 inhibitors |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| AR107912A1 (es) | 2016-03-17 | 2018-06-28 | Blueprint Medicines Corp | Inhibidores de ret |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| CN107844168B (zh) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | 主板组件及其卡扣装置 |
-
2016
- 2016-08-25 WO PCT/US2016/048698 patent/WO2017035354A1/en not_active Ceased
- 2016-08-25 JP JP2018510406A patent/JP6877407B2/ja not_active Expired - Fee Related
- 2016-08-25 HK HK18114466.6A patent/HK1255330A1/zh unknown
- 2016-08-25 CA CA2995997A patent/CA2995997A1/en not_active Abandoned
- 2016-08-25 MX MX2018002407A patent/MX2018002407A/es unknown
- 2016-08-25 BR BR112018003588A patent/BR112018003588A2/pt not_active IP Right Cessation
- 2016-08-25 KR KR1020187008146A patent/KR20180043810A/ko not_active Withdrawn
- 2016-08-25 AU AU2016311426A patent/AU2016311426B2/en not_active Expired - Fee Related
- 2016-08-25 EP EP16763630.7A patent/EP3341374A1/en not_active Withdrawn
- 2016-08-25 CN CN201680060799.0A patent/CN108137607B/zh not_active Expired - Fee Related
- 2016-08-25 RU RU2018110379A patent/RU2744974C2/ru active
- 2016-08-26 TW TW105127561A patent/TW201713665A/zh unknown
- 2016-08-26 AR ARP160102616A patent/AR105836A1/es unknown
- 2016-08-26 US US15/248,207 patent/US10017512B2/en active Active
-
2018
- 2018-02-22 PH PH12018500397A patent/PH12018500397A1/en unknown
- 2018-02-25 IL IL257702A patent/IL257702A/en unknown
- 2018-03-20 ZA ZA2018/01881A patent/ZA201801881B/en unknown
- 2018-07-03 US US16/027,166 patent/US11046697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1255330A1 (zh) | 2019-08-16 |
| US20170066773A1 (en) | 2017-03-09 |
| WO2017035354A1 (en) | 2017-03-02 |
| US20190169194A1 (en) | 2019-06-06 |
| PH12018500397A1 (en) | 2018-08-29 |
| AR105836A1 (es) | 2017-11-15 |
| BR112018003588A2 (pt) | 2018-09-25 |
| AU2016311426A1 (en) | 2018-04-05 |
| IL257702A (en) | 2018-04-30 |
| CN108137607A (zh) | 2018-06-08 |
| TW201713665A (zh) | 2017-04-16 |
| RU2744974C2 (ru) | 2021-03-17 |
| ZA201801881B (en) | 2019-05-29 |
| AU2016311426B2 (en) | 2021-05-20 |
| CA2995997A1 (en) | 2017-03-02 |
| EP3341374A1 (en) | 2018-07-04 |
| RU2018110379A3 (cg-RX-API-DMAC7.html) | 2019-12-26 |
| JP6877407B2 (ja) | 2021-05-26 |
| RU2018110379A (ru) | 2019-09-27 |
| JP2018528200A (ja) | 2018-09-27 |
| MX2018002407A (es) | 2018-11-29 |
| US10017512B2 (en) | 2018-07-10 |
| US11046697B2 (en) | 2021-06-29 |
| KR20180043810A (ko) | 2018-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255330A1 (zh) | 适用於治疗与ntrk相关的病症的化合物和组合物 | |
| US12595265B2 (en) | Inhibitors of activin receptor-like kinase | |
| US11059827B2 (en) | Compounds and compositions useful for treating disorders related to NTRK | |
| CN115192577A (zh) | Kras突变蛋白抑制剂 | |
| WO2024178304A1 (en) | Kras modulators | |
| CN110156813A (zh) | 作为trk抑制剂的杂环化合物 | |
| KR102713058B1 (ko) | 히스톤 아세틸라제 p300 억제제 및 그 용도 | |
| CN115867346A (zh) | 激酶抑制剂 | |
| TW202417449A (zh) | Cdk2抑制劑及使用彼等之方法 | |
| KR20250022815A (ko) | Hpk1 억제제 및 이의 의약품에서의 응용 | |
| HK40119973A (en) | Fused ring kras inhibitors for treating disease | |
| HK40065459A (en) | Kras mutant protein inhibitors | |
| BR122024013896A2 (pt) | Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1255330 Country of ref document: HK |
|
| CB02 | Change of applicant information |
Address after: Massachusetts, USA Applicant after: Cable chart pharmaceutical Co. Address before: Massachusetts, USA Applicant before: BLUEPRINT MEDICINES Corp. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210406 |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1255330 Country of ref document: HK |